NEW YORK (
CHANGE IN RATINGS, EPS
downgraded at BofA/Merrill from Buy to Neutral. Company is leveraged to the tractor market. $40 price target.
rated new Overweight at JP Morgan. $81 price target. Soliris should continue to drive growth.
numbers reduced at Keybanc.Shares of ATI now seen reaching $60. Estimates also cut, given lower nickel prices.
downgraded at Jefferies from Buy to Hold. New analyst expects higher credit losses in 2012. $50 price target.
upgraded at Rodman & Renshaw from Market Perform to Outperform. $5 price target. Company is not likely to declare bankruptcy and is attractively valued following a 33% decline.
estimates, target cut at UBS. Shares of AVP now seen reaching $31. Estimates also lowered on FX weakness and deterioration in investor sentiment. Maintain Buy rating.
upgraded at Goldman from Neutral to Buy. Company was also placed on the Conviction List. $50 price target. Company can continue to gain market share and buy back stock.
downgraded at Jefferies from Buy to Hold. $40 price target. New analyst believes that the stock lacks near-term catalysts.
rated new Outperform at Credit Suisse. $370 price target. Company should continue to deliver solid growth in the coming quarters.
added to Analyst Focus List at JP Morgan. The cable business is solid and the company is making steady improvements at NBC Universal. $30 price target.
estimates, target lowered at Citigroup.Shares of GLW now seen reaching $13. Estimates also lowered on negatively revised guidance.
estimates lowered at JP Morgan through 2015. Sapien could see fewer patients qualify for on-label usage. Underweight rating and $69 price target.
upgraded at Citigroup from Hold to Buy. $48 price target. EPA related market tightening should benefit the company.
rated new Outperform at OppenheimerESRX was initiated with an Outperform rating, Oppenheimer said. $54 price target. Stock is already pricing in a potential near-term earnings shortfall.
First Cash Financial
numbers cut at Sterne Agee.Shares of FCFS now seen reaching $38. Estimates also reduced, given currency headwinds. Underperform rating.
upgraded at Canaccord from Hold to Buy. $22 price target. Company has attractive assets, following the spin-off of its Canadian business.
downgraded to sell by TheStreet Ratings.
estimates cut at Wells through 2013. Company could see slower growth out of Europe. Outperform rating.
upgraded at Goldman from Neutral to Buy. Company was also placed on the Conviction List. $32 price target. Company offers a solid dividend yield as well as growth.
downgraded at Goldman from Buy to Neutral. Valuation call, based on a $123 price target.
rated new Buy at Guggenheim Securities. Company can deliver above-average growth and deserves a premium valuation.
cut from Conviction Buy List at Goldman Sachs. Valuation call, based on a $17 price target.
downgraded to hold by TheStreet Ratings.
estimates, target lowered at UBS.Shares of NRG now seen reaching $25. Estimates also cut on lowered guidance due to extreme heat in Texas. Maintain Buy rating.
Pharmaceutical Product Development
( PPDI) downgraded at Citigroup from Buy to Hold. $33.25 price target. Company has entered a definitive merger agreement with The Carlyle Group and Hellman & Friedman.
rated new Equal-weight at Morgan Stanley. Stock is already factoring in high expectations, despite macro uncertainty.
upgraded at Jefferies from Hold to Buy. $57 price target. Valuation call, as the stock has sold off 27% since early July.
downgraded at Argus from Buy to Hold. Sluggish economy has hurt packaging demand.
estimates raised at Goldman through 2013. Company is leveraged to a stronger yen.
upgraded at JMP to Market Outperform. $53 price target. Incivek should continue to drive near-term growth.
rated new Outperform at Morgan Stanley. $148 price target. Company can double its sales through international growth.
rated new Neutral at Guggenheim Securities. Valuation call, as the company could possibly lose market share in the debit card market.
estimates cut at Goldman through 2013. Company could be hurt by the stronger dollar.
rated new Underweight at Morgan Stanley. $43 price target. Company lacks pricing power and is facing rising input costs.
Wolverine World Wide
estimates increased at Credit Suisse through 2013. Company is realizing higher margins. Outperform rating and $44 price target.
This article was written by a staff member of TheStreet.